Dendritic Cell Cancer Vaccine Global Market Report 2024

Description

Dendritic cell cancer vaccines are immunotherapies that leverage the body's dendritic cells to stimulate an immune response against cancer cells, potentially enhancing the body's ability to recognize and destroy tumors. They represent a personalized treatment approach tailored to target specific types of cancer, aiming to bolster the immune system's capacity to combat the disease. By harnessing the body's immune system, dendritic cell cancer vaccines hold promise for eliciting more effective and durable responses in patients.

The main products in the realm of dendritic cell cancer vaccines include CreaVax, Sipuleucel-T (Provenge), and others. CreaVax is a dendritic cell cancer vaccine crafted to activate the body's immune response against cancer cells, employing specialized immune cells loaded with tumor-specific antigens. These products are typically distributed through hospitals, cancer centers, ambulatory surgical centers, and clinics, with applications extending to both pediatric and adult populations. End users encompass oncology practitioners, research institutions, and biopharmaceutical companies alike.

The dendritic cell cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides dendritic cell cancer vaccine market statistics, including the dendritic cell cancer vaccine industry global market size, regional shares, competitors with the dendritic cell cancer vaccine market share, detailed dendritic cell cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the dendritic cell cancer vaccine industry. These dendritic cell cancer vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dendritic cell cancer vaccine market size has grown rapidly in recent years. It will grow from $2.23 billion in 2023 to $2.46 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to several factors, including cancer awareness initiatives that have heightened public understanding and engagement, investments in manufacturing infrastructure to support the production of innovative therapies, exploration of combination therapies that leverage multiple treatment modalities for enhanced efficacy, adoption of precision medicine approaches that tailor treatments to individual patients, and improved understanding of the immune system's role in cancer surveillance and response.

The dendritic cell cancer vaccine market size is expected to see rapid growth in the next few years. It will grow to $3.63 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to several factors, including the integration of omics technologies into cancer research and treatment, the global aging population leading to a higher incidence of cancer, the emergence of digital health solutions that facilitate personalized care and monitoring, increasing patient advocacy efforts and awareness campaigns that promote early detection and treatment, the integration of artificial intelligence (AI) to enhance diagnosis and treatment planning, and a focus on biomarker-driven therapies for more targeted and effective treatments. Major trends in the forecast period include advances in regenerative medicine for tissue repair and regeneration, innovations in vaccine delivery systems to improve efficacy and accessibility, a shift towards patient-centric drug development that considers individual needs and preferences, advancements in neoantigen identification for personalized cancer vaccines, and the development of next-generation vaccine platforms for broader and more effective immunization strategies.

The dendritic cell cancer vaccine market is poised for growth driven by the increasing incidence of cancer cases. Cancer, characterized by the uncontrolled proliferation of abnormal cells, is influenced by various factors including lifestyle choices, environmental factors, and genetic predispositions. Dendritic cell cancer vaccines play a crucial role in cancer treatment by activating the body's immune system to target cancer cells, potentially leading to improved patient outcomes. For example, projections from the World Health Organisation suggest a substantial increase in cancer cases by 2050, highlighting the urgent need for innovative treatments such as dendritic cell cancer vaccines to address this growing healthcare challenge.

Key players in the dendritic cell cancer vaccine market are actively engaged in forming strategic partnerships to advance the development of curative cancer vaccines and enhance clinical care for patients. These collaborations, aimed at achieving mutual business objectives, facilitate the pooling of resources and expertise to accelerate vaccine development. For instance, the Walter and Eliza Hall Institute of Medical Research partnered with the Peter MacCallum Cancer Centre to receive substantial funding for the development of a cancer vaccine targeting patients with limited therapeutic options. This collaboration builds upon pioneering research conducted three decades ago, with the potential to initiate groundbreaking clinical trials for cancer patients.

In March 2021, Charles River Laboratories International Inc. expanded its capabilities by acquiring Cognate BioServices Inc., a leading provider of contract development services for autologous dendritic cell vaccines. This strategic acquisition enables Charles River Laboratories to offer integrated solutions to clients, combining manufacturing with essential analytical testing to streamline processes and accelerate the time-to-market for novel dendritic cell vaccine candidates.

Major companies operating in the dendritic cell cancer vaccine market are Dendreon Pharmaceuticals LLC, Celgene Corporation, Cognate BioServices Inc., APAC Biotech, Asterias Biotherapeutics Inc, Batavia Biosciences, Medigene AG, Zelluna Immunotherapy AS, Diakonos Oncology, Elios Therapeutics LLC, Northwest Biotherapeutics, Oncopep Inc., PDC*line Pharma SA, SillaJen Biotherapeutics Inc., VLP Therapeutics, ImmunityBio Inc., Celldex Therapeutics Inc., Bellicum Pharmaceuticals, Argos Therapeutics Inc., DCPrime, NuGenerex Immuno-Oncology

North America was the largest region in the dendritic cell cancer vaccine market in 2023. The regions covered in the dendritic cell cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dendritic cell cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dendritic cell cancer vaccines market consists of sales of autologous dendritic cell vaccines, allogeneic dendritic cell vaccines, and experimental vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dendritic Cell Cancer Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dendritic cell cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dendritic cell cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dendritic cell cancer vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: CreaVax; Sipuleucel-T (Provenge); Other Products
2) By Distribution Channel: Hospitals; Cancer Centers; Ambulatory Surgical Centers; Clinics
3) By Application: Pediatrics; Adults
4) By End User: Oncology; Research Institutions; Biopharmaceutical Companies
Companies Mentioned: Dendreon Pharmaceuticals LLC; Celgene Corporation; Cognate BioServices Inc.; APAC Biotech; Asterias Biotherapeutics Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r18582

1. Executive Summary

2. Dendritic Cell Cancer Vaccine Market Characteristics

3. Dendritic Cell Cancer Vaccine Market Trends And Strategies

4. Dendritic Cell Cancer Vaccine Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Dendritic Cell Cancer Vaccine Market Size and Growth

5.1. Global Dendritic Cell Cancer Vaccine Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Dendritic Cell Cancer Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Dendritic Cell Cancer Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Dendritic Cell Cancer Vaccine Market Segmentation

6.1. Global Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
CreaVax
Sipuleucel-T (Provenge)
Other Products
6.2. Global Dendritic Cell Cancer Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Cancer Centers
Ambulatory Surgical Centers
Clinics
6.3. Global Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Pediatrics
Adults
6.4. Global Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oncology
Research Institutions
Biopharmaceutical Companies

7. Dendritic Cell Cancer Vaccine Market Regional And Country Analysis

7.1. Global Dendritic Cell Cancer Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Dendritic Cell Cancer Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Dendritic Cell Cancer Vaccine Market

8.1. Asia-Pacific Dendritic Cell Cancer Vaccine Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Dendritic Cell Cancer Vaccine Market

9.1. China Dendritic Cell Cancer Vaccine Market Overview
9.2. China Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Dendritic Cell Cancer Vaccine Market

10.1. India Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Dendritic Cell Cancer Vaccine Market

11.1. Japan Dendritic Cell Cancer Vaccine Market Overview
11.2. Japan Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Dendritic Cell Cancer Vaccine Market

12.1. Australia Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Dendritic Cell Cancer Vaccine Market

13.1. Indonesia Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Dendritic Cell Cancer Vaccine Market

14.1. South Korea Dendritic Cell Cancer Vaccine Market Overview
14.2. South Korea Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Dendritic Cell Cancer Vaccine Market

15.1. Western Europe Dendritic Cell Cancer Vaccine Market Overview
15.2. Western Europe Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Dendritic Cell Cancer Vaccine Market

16.1. UK Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Dendritic Cell Cancer Vaccine Market

17.1. Germany Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Dendritic Cell Cancer Vaccine Market

18.1. France Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Dendritic Cell Cancer Vaccine Market

19.1. Italy Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Dendritic Cell Cancer Vaccine Market

20.1. Spain Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Dendritic Cell Cancer Vaccine Market

21.1. Eastern Europe Dendritic Cell Cancer Vaccine Market Overview
21.2. Eastern Europe Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Dendritic Cell Cancer Vaccine Market

22.1. Russia Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Dendritic Cell Cancer Vaccine Market

23.1. North America Dendritic Cell Cancer Vaccine Market Overview
23.2. North America Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Dendritic Cell Cancer Vaccine Market

24.1. USA Dendritic Cell Cancer Vaccine Market Overview
24.2. USA Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Dendritic Cell Cancer Vaccine Market

25.1. Canada Dendritic Cell Cancer Vaccine Market Overview
25.2. Canada Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Dendritic Cell Cancer Vaccine Market

26.1. South America Dendritic Cell Cancer Vaccine Market Overview
26.2. South America Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Dendritic Cell Cancer Vaccine Market

27.1. Brazil Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Dendritic Cell Cancer Vaccine Market

28.1. Middle East Dendritic Cell Cancer Vaccine Market Overview
28.2. Middle East Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Dendritic Cell Cancer Vaccine Market

29.1. Africa Dendritic Cell Cancer Vaccine Market Overview
29.2. Africa Dendritic Cell Cancer Vaccine Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Dendritic Cell Cancer Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Dendritic Cell Cancer Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Dendritic Cell Cancer Vaccine Market Competitive Landscape And Company Profiles

30.1. Dendritic Cell Cancer Vaccine Market Competitive Landscape
30.2. Dendritic Cell Cancer Vaccine Market Company Profiles
- 30.2.1. Dendreon Pharmaceuticals LLC
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Celgene Corporation
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Cognate BioServices Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. APAC Biotech
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Asterias Biotherapeutics Inc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Dendritic Cell Cancer Vaccine Market Other Major And Innovative Companies

31.1. Batavia Biosciences
31.2. Medigene AG
31.3. Zelluna Immunotherapy AS
31.4. Diakonos Oncology
31.5. Elios Therapeutics LLC
31.6. Northwest Biotherapeutics
31.7. Oncopep Inc.
31.8. PDC*line Pharma SA
31.9. SillaJen Biotherapeutics Inc.
31.10. VLP Therapeutics
31.11. ImmunityBio Inc.
31.12. Celldex Therapeutics Inc.
31.13. Bellicum Pharmaceuticals
31.14. Argos Therapeutics Inc.
31.15. DCPrime

32. Global Dendritic Cell Cancer Vaccine Market Competitive Benchmarking

33. Global Dendritic Cell Cancer Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Dendritic Cell Cancer Vaccine Market

35. Dendritic Cell Cancer Vaccine Market Future Outlook and Potential Analysis

35.1 Dendritic Cell Cancer Vaccine Market In 2028 - Countries Offering Most New Opportunities
35.2 Dendritic Cell Cancer Vaccine Market In 2028 - Segments Offering Most New Opportunities
35.3 Dendritic Cell Cancer Vaccine Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer